These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1003 related items for PubMed ID: 26205801

  • 1. Therapeutic efficacy of different iron chelators in Egyptian children with Beta Thalassemia with iron overload.
    Hagag AA, Hamam MA, Taha OA, Hazaa SM.
    Infect Disord Drug Targets; 2015; 15(2):98-105. PubMed ID: 26205801
    [Abstract] [Full Text] [Related]

  • 2. Deferasirox for managing iron overload in people with thalassaemia.
    Bollig C, Schell LK, Rücker G, Allert R, Motschall E, Niemeyer CM, Bassler D, Meerpohl JJ.
    Cochrane Database Syst Rev; 2017 Aug 15; 8(8):CD007476. PubMed ID: 28809446
    [Abstract] [Full Text] [Related]

  • 3. Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia.
    Fisher SA, Brunskill SJ, Doree C, Gooding S, Chowdhury O, Roberts DJ.
    Cochrane Database Syst Rev; 2013 Aug 21; 2013(8):CD004450. PubMed ID: 23963793
    [Abstract] [Full Text] [Related]

  • 4. Therapeutic value of combined therapy with deferiprone and silymarin as iron chelators in Egyptian children with beta thalassemia major.
    Hagag AA, Elfaragy MS, Elrifaey SM, Abd El-Lateef AE.
    Infect Disord Drug Targets; 2015 Aug 21; 15(3):189-95. PubMed ID: 26239735
    [Abstract] [Full Text] [Related]

  • 5. Comparative Efficacy and Safety of Oral Iron Chelators and their Novel Combination in Children with Thalassemia.
    Gomber S, Jain P, Sharma S, Narang M.
    Indian Pediatr; 2016 Mar 21; 53(3):207-10. PubMed ID: 27029681
    [Abstract] [Full Text] [Related]

  • 6. The deferiprone and deferasirox combination is efficacious in iron overloaded patients with β-thalassemia major: A prospective, single center, open-label study.
    Totadri S, Bansal D, Bhatia P, Attri SV, Trehan A, Marwaha RK.
    Pediatr Blood Cancer; 2015 Sep 21; 62(9):1592-6. PubMed ID: 25820920
    [Abstract] [Full Text] [Related]

  • 7. Deferasirox, deferiprone and desferrioxamine treatment in thalassemia major patients: cardiac iron and function comparison determined by quantitative magnetic resonance imaging.
    Pepe A, Meloni A, Capra M, Cianciulli P, Prossomariti L, Malaventura C, Putti MC, Lippi A, Romeo MA, Bisconte MG, Filosa A, Caruso V, Quarta A, Pitrolo L, Missere M, Midiri M, Rossi G, Positano V, Lombardi M, Maggio A.
    Haematologica; 2011 Jan 21; 96(1):41-7. PubMed ID: 20884710
    [Abstract] [Full Text] [Related]

  • 8. Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload.
    Daar S, Pathare AV.
    Ann Hematol; 2006 May 21; 85(5):315-9. PubMed ID: 16450126
    [Abstract] [Full Text] [Related]

  • 9. Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions.
    Neufeld EJ.
    Blood; 2006 May 01; 107(9):3436-41. PubMed ID: 16627763
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and safety of a novel combination of two oral chelators deferasirox/deferiprone over deferoxamine/deferiprone in severely iron overloaded young beta thalassemia major patients.
    Elalfy MS, Adly AM, Wali Y, Tony S, Samir A, Elhenawy YI.
    Eur J Haematol; 2015 Nov 01; 95(5):411-20. PubMed ID: 25600572
    [Abstract] [Full Text] [Related]

  • 11. Clinical monitoring and management of complications related to chelation therapy in patients with β-thalassemia.
    Saliba AN, El Rassi F, Taher AT.
    Expert Rev Hematol; 2016 Nov 01; 9(2):151-68. PubMed ID: 26613264
    [Abstract] [Full Text] [Related]

  • 12. Daily alternating deferasirox and deferiprone therapy for "hard-to-chelate" beta-thalassemia major patients.
    Balocco M, Carrara P, Pinto V, Forni GL.
    Am J Hematol; 2010 Jun 01; 85(6):460-1. PubMed ID: 20513129
    [No Abstract] [Full Text] [Related]

  • 13. Differential effects of iron chelators on iron burden and long-term morbidity and mortality outcomes in a large cohort of transfusion-dependent β-thalassemia patients who remained on the same monotherapy over 10 years.
    Musallam KM, Barella S, Origa R, Ferrero GB, Lisi R, Pasanisi A, Longo F, Gianesin B, Forni GL, Webthal® project.
    Blood Cells Mol Dis; 2024 Jul 01; 107():102859. PubMed ID: 38820707
    [Abstract] [Full Text] [Related]

  • 14. Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia.
    Fortin PM, Fisher SA, Madgwick KV, Trivella M, Hopewell S, Doree C, Estcourt LJ.
    Cochrane Database Syst Rev; 2018 May 08; 5(5):CD012349. PubMed ID: 29737522
    [Abstract] [Full Text] [Related]

  • 15. Combination of deferasirox and deferoxamine in clinical practice: an alternative scheme of chelation in thalassemia major patients.
    Cassinerio E, Orofino N, Roghi A, Duca L, Poggiali E, Fraquelli M, Zanaboni L, Cappellini MD.
    Blood Cells Mol Dis; 2014 Sep 08; 53(3):164-7. PubMed ID: 24846580
    [Abstract] [Full Text] [Related]

  • 16. Timed non-transferrin bound iron determinations probe the origin of chelatable iron pools during deferiprone regimens and predict chelation response.
    Aydinok Y, Evans P, Manz CY, Porter JB.
    Haematologica; 2012 Jun 08; 97(6):835-41. PubMed ID: 22180427
    [Abstract] [Full Text] [Related]

  • 17. Comparison of oral iron chelators in the management of transfusion-dependent β-thalassemia major based on serum ferritin and liver enzymes.
    Yusuf S, Herdata HN, Edward ED, Khairunnisa K.
    F1000Res; 2023 Jun 08; 12():154. PubMed ID: 39233713
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia: the ESCALATOR study.
    Taher A, El-Beshlawy A, Elalfy MS, Al Zir K, Daar S, Habr D, Kriemler-Krahn U, Hmissi A, Al Jefri A.
    Eur J Haematol; 2009 Jun 08; 82(6):458-65. PubMed ID: 19187278
    [Abstract] [Full Text] [Related]

  • 19. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance.
    Tanner MA, Galanello R, Dessi C, Smith GC, Westwood MA, Agus A, Roughton M, Assomull R, Nair SV, Walker JM, Pennell DJ.
    Circulation; 2007 Apr 10; 115(14):1876-84. PubMed ID: 17372174
    [Abstract] [Full Text] [Related]

  • 20. Oral deferiprone for iron chelation in people with thalassaemia.
    Fisher SA, Brunskill SJ, Doree C, Chowdhury O, Gooding S, Roberts DJ.
    Cochrane Database Syst Rev; 2013 Aug 21; (8):CD004839. PubMed ID: 23966105
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 51.